Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H28N2O3 |
Molecular Weight | 380.48 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
InChI
InChIKey=UUOJIACWOAYWEZ-UHFFFAOYSA-N
InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
Molecular Formula | C23H28N2O3 |
Molecular Weight | 380.48 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11314603 | https://www.ncbi.nlm.nih.gov/pubmed/1706984
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11314603 | https://www.ncbi.nlm.nih.gov/pubmed/1706984
Bopindolol (4-[benzoyloxy-3-tertbutylaminopropoxy]-2-methylindole hydrogen malonate) is an indole beta-adrenoceptor antagonist bearing a benzoyl ester residue on the beta-carbon atom of the propanolamine side chain. Bopindolol is metabolized by esterase to benzoic acid and an active metabolite, 18-502
[4-(3-t-butylamino-2-hydroxypropoxy)-2-methyl indole], which is further metabolized to
20-785 [4-(3-t-butylaminopropoxy)-2-carboxyl indole]. Bopindolol produces sustained blockade of beta 1- and beta 2-adrenoceptors, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Bopindolol is used in the treatment of hypertension. In limited trials bopindolol has also successfully reduced symptoms in patients with angina pectoris, anxiety and essential tremor.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
7.44 null [pKi] | ||
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
7.33 null [pKi] | ||
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11314603 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BOPINDOLOL Approved UseBopindolol is a nonselective beta-adrenoceptor antagonist with partial agonist activity which is used in the treatment of hypertension. |
PubMed
Title | Date | PubMed |
---|---|---|
Beta-blockers and psychic stress: a double-blind, placebo-controlled study of bopindolol vs lorazepam and butalbital in surgical patients. | 1985 Sep |
|
Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. | 1991 Jan |
|
[Multicenter study of isradipine in the treatment of hypertension]. | 1992 Apr |
|
Hypotensive effect of bopindolol in pithed rats. | 1993 Mar |
|
Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension. | 1998 |
|
Effect of vasodilatory beta-adrenoceptor blockers on cardiovascular haemodynamics in anaesthetized rats. | 2002 Mar |
|
Determination of bopindolol by sequential injection technique with spectrophotometric detection. | 2003 Oct |
|
Role of chemical structure in stereoselective recognition of beta-blockers by cyclodextrins in capillary zone electrophoresis. | 2008 Apr 24 |
|
Chiral separations of some beta-adrenergic agonists and antagonists on AmyCoat column by HPLC. | 2010 Jan |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1706984
antihypertensive effects of bopindolol 0.5 to 4 mg are sustained for more than 24 hours after once daily dosing
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:27:18 GMT 2023
by
admin
on
Fri Dec 15 17:27:18 GMT 2023
|
Record UNII |
KT304VZO57
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07AA17
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
||
|
WHO-VATC |
QC07AA17
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
||
|
WHO-ATC |
C07CA17
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05873MIG
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
100000088637
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
4695
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
19605
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
62658-63-3
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
C169813
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
DB08807
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
76749
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
DTXSID6022684
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
KT304VZO57
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
44112
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
m2605
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
389
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
BOPINDOLOL
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL357995
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY | |||
|
C036007
Created by
admin on Fri Dec 15 17:27:18 GMT 2023 , Edited by admin on Fri Dec 15 17:27:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |